Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_assertion type Assertion NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_head.
- NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_assertion description "[The risks of hepatic injury were higher after anti-tuberculosis therapy in patients carrying the NAT2 slow acetylator, CYP2E1 -1259G>C, -1019C>T wild-type, and GSTM1 null genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_provenance.
- NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_assertion evidence source_evidence_literature NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_provenance.
- NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_assertion SIO_000772 25501156 NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_provenance.
- NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_assertion wasDerivedFrom befree-2016 NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_provenance.
- NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_assertion wasGeneratedBy ECO_0000203 NP1247480.RArpYkEbfh7hRv1sPaRFGatkrBRTf_fQl8czw7r8kwTl8130_provenance.